TABLE 3.

Impact of HPV-16/18 vaccination on infections prevalent at vaccination

HPV Types	Cohort	Outcome	Arm	No. infections	No. events	No. person-years	Rate per 1000	% vaccine efficacy	95% CI
HPV-16/18	Infected women without precancer	Clearance	HPV	268	243	492	489	−5.4%	[−19, 10]
			Ctrl	313	298	569	517
		CIN1+	HPV	244	32	1200	28.0	−15.5%	[−86, 28]
			Ctrl	295	35	1427	24.2
		CIN2+	HPV	258	25	1301	20.2	0.3%	[−69, 41]
			Ctrl	308	31	1504	20.3
	Infected women without cytologic abnormalities	Clearance	HPV	173	160	326	481	−3.3%	[−19, 16]
			Ctrl	216	208	403	497
		LSIL+	HPV	171	62	642	77.2	−3.5%	[−85, 42]
			Ctrl	216	71	861	74.6
		HSIL+a	HPV	161	23	744	30.9	−48.6%	[−172, 19]
			Ctrl	200	20	961	20.8
		CIN1+	HPV	171	23	835	28.5	5.5%	[−60, 44]
			Ctrl	214	32	1035	30.2
		CIN2+	HPV	171	17	849	20.7	22.6%	[−40, 57]
			Ctrl	215	29	1050	26.8
HPV-31/33/45	Infected women without precancer	Clearance	HPV	214	206	323	617	4.0%	[−13, 24]
			Ctrl	222	211	348	594
		CIN1+	HPV	201	17	938	18.3	14.0%	[−62, 54]
			Ctrl	210	22	1020	21.3
		CIN2+	HPV	208	14	986	14.4	17.4%	[−65, 59]
			Ctrl	218	19	1070	17.4
	Infected women without cytological abnormalities	Clearance	HPV	144	138	219	617	9.3%	[−12, 35]
			Ctrl	159	151	261	564
		LSIL+	HPV	144	32	578	52.4	−4.2%	[−79, 39]
			Ctrl	158	41	662	50.3
		HSIL+	HPV	144	13	653	20.1	4.2%	[−101, 54]
			Ctrl	158	17	749	21
		CIN1+	HPV	144	14	656	21.5	17.6%	[−63, 58]
			Ctrl	157	20	753	26.1
		CIN2+	HPV	144	12	663	18.2	15.7%	[−76, 60]
			Ctrl	157	17	763	21.6
Oncogenic HPV	Infected women without precancer	Clearance	HPV	1198	1149	1761	599	4.8%	[−3.7, 14]
			Ctrl	1236	1184	1881	571
		CIN1+	HPV	1110	83	5487	14.0	−0.9%	[−42, 28]
			Ctrl	1149	89	5646	13.9
		CIN2+	HPV	1160	62	5817	9.6	3.1%	[−45, 35]
			Ctrl	1208	68	6004	9.9
	Infected women without cytologic abnormalities	Clearance	HPV	788	758	1195	575	1.0%	[−8.8, 12]
			Ctrl	854	822	1311	569
		LSIL+	HPV	779	191	3242	45.2	−10.7%	[−45, 16]
			Ctrl	847	197	3615	40.8
		HSIL+	HPV	779	64	3750	14.3	−19.2%	[−84, 23]
			Ctrl	847	62	4128	12
		CIN1+	HPV	779	62	3814	15.5	6.7%	[−35, 35]
			Ctrl	842	76	4130	16.6
		CIN2+	HPV	779	46	3862	10.8	15.0%	[−31, 45]
			Ctrl	845	59	4188	12.8

CI, confidence interval; CIN1, cervical intraepithelial neoplasia type 1; CIN2, cervical intraepithelial neoplasia type 2; HPV, human papillomavirus; HSIL, high-grade squamous intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion.

^aExcludes 5 individuals from the HPV arm and 8 individuals from the control arm with both HPV16 and HPV18 infections to allow for model conversion.